The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors

被引：69

作者：

Dodson, Thomas B. ^{[1
]}

机构：

[1] Univ Washington, Sch Dent, Dept Oral & Maxillofacial Surg, Seattle, WA 98195 USA

来源：

ORAL AND MAXILLOFACIAL SURGERY CLINICS OF NORTH AMERICA | 2015年 / 27卷 / 04期

关键词：

Medication-related osteonecrosis of the jaws; Frequency; Risk factors; Zolendronate; Oral bisphosphonates; Antiresorptive medications; Antiangiogenic agents; BISPHOSPHONATE-INDUCED OSTEONECROSIS; ZOLEDRONIC ACID; BREAST-CANCER; BONE METASTASES; DENOSUMAB EXPOSURE; MULTIPLE-MYELOMA; TOOTH EXTRACTION; OPEN-LABEL; THERAPY; OUTCOMES;

D O I：

10.1016/j.coms.2015.06.003

中图分类号：

R78 [口腔科学];

学科分类号：

1003 ;

摘要：

This article provides the best current frequency estimate of medication-related osteonecrosis of the jaws (MRONJ) and identifies factors associated with the risk of developing osteonecrosis of the jaw (ONJ) among patients exposed to relevant medications (ie, antiresorptive or antiangiogenic agents). MRONJ is a rare but serious complication of cancer treatment or osteoporosis management. This review confirms that antiresorptive medications such as oral or intravenous bisphosphonates and denosumab are the most common risk factors for developing ONJ. The risk of MRONJ is greater in patients with cancer than in those receiving antiresorptive treatments for osteoporosis by a factor of 10.

引用

页码：509 / +

页数：10

共 43 条

[1]

Background document for meeting of Advisory Committee for Reproductive Health Drugs and Drug Safety and Risk Management Advisory Committee, 2011, BACKGR DOC M ADV COM, P14

[2] New approach to analyze genetic and clinical data in bisphosphonate-induced osteonecrosis of the jaw [J].

Balla, B. ;

Vaszilko, M. ;

Kosa, J. P. ;

Podani, J. ;

Takacs, I. ;

Tobias, B. ;

Nagy, Z. ;

Lazary, A. ;

Lakatos, P. .

ORAL DISEASES, 2012, 18 (06) :580-585

[3] Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial [J].

Barrett-Lee, Peter ;

Casbard, Angela ;

Abraham, Jacinta ;

Hood, Kerenza ;

Coleman, Robert ;

Simmonds, Peter ;

Timmins, Hayley ;

Wheatley, Duncan ;

Grieve, Robert ;

Griffithst, Gareth ;

Murray, Nick .

LANCET ONCOLOGY, 2014, 15 (01) :114-122

[4] The Effect of Three or Six Years of Denosumab Exposure in Women With Postmenopausal Osteoporosis: Results From the FREEDOM Extension [J].

Bone, Henry G. ;

Chapurlat, Roland ;

Brandi, Maria-Luisa ;

Brown, Jacques P. ;

Czerwinski, Edward ;

Krieg, Marc-Antoine ;

Mellstrom, Dan ;

Radominski, Sebastiao C. ;

Reginster, Jean-Yves ;

Resch, Heinrich ;

Roman Ivorra, Jose A. ;

Roux, Christian ;

Vittinghoff, Eric ;

Daizadeh, Nadia S. ;

Wang, Andrea ;

Bradley, Michelle N. ;

Franchimont, Nathalie ;

Geller, Michelle L. ;

Wagman, Rachel B. ;

Cummings, Steven R. ;

Papapoulos, Socrates .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2013, 98 (11) :4483-4492

[5] A Large Case-Control Study Reveals a Positive Association Between Bisphosphonate Use and Delayed Dental Healing and Osteonecrosis of the Jaw [J].

Borromeo, Gelsomina L. ;

Brand, Caroline ;

Clement, John G. ;

McCullough, Michael ;

Crighton, Lisa ;

Hepworth, Graham ;

Wark, John D. .

JOURNAL OF BONE AND MINERAL RESEARCH, 2014, 29 (06) :1363-1368

[6] Zoledronic acid treatment for cancerous bone metastases: A phase IV study in Taiwan [J].

Chiang, Po-Hui ;

Wang, Hwei-Chung ;

Lai, Yuen-Liang ;

Chen, Shin-Cheh ;

Yen-Hwa, Wayne ;

Kok, Chit-Kheng ;

Ou, Yen-Chuan ;

Huang, Jen-Shen ;

Huang, Tzu-Chuan ;

Chao, Tsu-Yi .

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2013, 9 (04) :653-659

[7] Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial [J].

Coleman, Robert ;

Cameron, David ;

Dodwell, David ;

Bell, Richard ;

Wilson, Caroline ;

Rathbone, Emma ;

Keane, Maccon ;

Gil, Miguel ;

Burkinshaw, Roger ;

Grieve, Robert ;

Barrett-Lee, Peter ;

Ritchie, Diana ;

Liversedge, Victoria ;

Hinsley, Samantha ;

Marshall, Helen .

LANCET ONCOLOGY, 2014, 15 (09) :997-1006

[8] Bisphosphonate-induced osteonecrosis of the jaw (ONJ): Incidence and risk factors in patients with breast cancer and gynecological malignancies [J].

Fehm, T. ;

Beck, V. ;

Banys, M. ;

Lipp, H. P. ;

Hairass, M. ;

Reinert, S. ;

Solomayer, E. F. ;

Wallwiener, D. ;

Krimmel, M. .

GYNECOLOGIC ONCOLOGY, 2009, 112 (03) :605-609

[9]

Felsenberg D, 2006, DTSCH ARZTEBL, V103, P3078

[10] Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12 [J].

Gnant, M. ;

Mlineritsch, B. ;

Stoeger, H. ;

Luschin-Ebengreuth, G. ;

Knauer, M. ;

Moik, M. ;

Jakesz, R. ;

Seifert, M. ;

Taucher, S. ;

Bjelic-Radisic, V. ;

Balic, M. ;

Eidtmann, H. ;

Eiermann, W. ;

Steger, G. ;

Kwasny, W. ;

Dubsky, P. ;

Selim, U. ;

Fitzal, F. ;

Hochreiner, G. ;

Wette, V. ;

Sevelda, P. ;

Ploner, F. ;

Bartsch, R. ;

Fesl, C. ;

Greil, R. .

ANNALS OF ONCOLOGY, 2015, 26 (02) :313-320

← 1 2 3 4 5 →